When Will Ozempic Go Generic? The Real Timeline for Semaglutide

The main US patent covering semaglutide itself — the active ingredient in Ozempic, Wegovy, and Rybelsus — is US 8,129,343, titled “Acylated GLP-1 compounds,” and it expires in December 2031 ^[1][2][3]. That is the date most often quoted as “when Ozempic goes generic.” But a patent expiring is not the same as a generic appearing on a pharmacy shelf. Novo Nordisk has built a layered set of follow-on patents on formulations, methods of treatment, and injection devices, and several of those run into the late 2030s and early 2040s ^[1][3]. One commercial patent-tracking service, Pharsight, estimates the US generic launch date for Wegovy at February 17, 2041 based on its current patent list ^[3] — an estimate, not an official date, and one that litigation could move in either direction.

The spread of dates a reader encounters comes from which patent a given source is looking at: the original 20-year term that ran to March 2026, a date cited by I-MAK and reflected in one expired patent on Pharsight’s listing ^[1][3]; the extended compound patent at December 2031 ^[1][2][3]; and the follow-on patents layered on top, which run from 2033 into the early 2040s on Pharsight’s list ^[3], with DrugPatentWatch noting that many listed Ozempic device patents run to the late 2030s ^[2]. Each of those produces a different “expiration date” for what is really the same drug.

Why do some sources say semaglutide’s patent already expired in March 2026?

Pharsight’s patent listing for Wegovy shows two US compound patents with the same title, “Acylated GLP-1 compounds.” The first, US 8,129,343, remains active and expires in December 2031 ^[1][2][3]. The second, US 8,536,122, is listed as expired with a March 2026 expiry date ^[3].

The patent advocacy organization I-MAK explains the gap: the main compound patent would technically have expired in March 2026, which is twenty years from when it was filed, but its term was extended by more than five years through a Patent Term Adjustment (compensating for USPTO processing delays) and a Patent Term Extension (compensating for FDA review time) ^[1]. I-MAK conservatively estimates that in just those five extra years, Novo Nordisk stands to earn $166 billion in revenue across Ozempic, Rybelsus, and Wegovy ^[1].

So March 2026 was the original 20-year filing date, not the operative US expiration date. Semaglutide is not off patent in the US, and the December 2031 date on US 8,129,343 is the one that governs the compound itself ^[1][2][3].

Why doesn’t a patent expiring mean a generic launches?

Because the compound patent is only the first layer. I-MAK counts 320 US patent applications filed by Novo Nordisk related to Ozempic, Rybelsus, and Wegovy, with 154 patents granted ^[1]. Of those, 49 granted patents expire after the main compound patent and, according to I-MAK, extend protection by about ten more years, to 2042 ^[1]. The majority of these follow-on filings cover delivery devices, formulations, and methods of treatment rather than the molecule itself ^[1].

DrugPatentWatch, a commercial patent-analysis service, describes the same structure: compound patents (the amino acid sequence itself) are the hardest to design around and typically expire first, while formulation, method-of-use, and device patents stack on top ^[2]. Novo Nordisk has listed over 20 patents for Ozempic, many covering the injection device, some running to the late 2030s ^[2]. Across GLP-1 products, 54% of all patents listed for them cover delivery devices rather than the drugs themselves, and the median product carries 19.5 patents listed in the FDA’s Orange Book ^[2].

Device patents matter because listing them in the Orange Book can trigger a 30-month stay that blocks generic approval while litigation proceeds ^[2]. The FTC has challenged such device listings as improper where the patents do not recite the active ingredient ^[2].

What patents protect Wegovy, and when do they expire?

Pharsight’s listing for Wegovy shows 18 US drug patents, 17 active and 1 expired, with the earliest challenge window open since December 5, 2021 ^[3]. Here is the ladder of expiry dates as Pharsight lists them ^[3]:

Patent	What it covers	Expiry	Status
US 8,129,343	Acylated GLP-1 compounds (the molecule)	Dec 2031	Active
US 8,536,122	Acylated GLP-1 compounds	Mar 2026	Expired
US 9278123 / US 11382957	Solid compositions, GLP-1 agonist + SNAC salt	Dec 2031	Active
US 9764003 / US 11033499	Use of long-acting GLP-1 peptides; tablet formulation	Jun 2033	Active
US 10278923 / US 12239739	Oral dosing of GLP-1 compounds	May 2034	Active
US 12569543	Semaglutide in cardiovascular conditions	Apr 2037	Active
US 10888605 / US 11752198 / US 12214017	GLP-1 compositions and uses	Aug 2038	Active
US 12029779 / US 12551536	Semaglutide in medical therapy	Oct 2038	Active
US 11833248 / US 12396953	Solid oral compositions with SNAC salt	Feb 2039	Active
US 11478533	Semaglutide for use in medicine	May 2040	Active
US 11318191	GLP-1 compositions and uses	Feb 2041	Active, litigated

Based on this list, Pharsight estimates Wegovy’s generic launch date at February 17, 2041 ^[3]. That is a model-based estimate from one commercial tracker, not a regulatory fact — a successful patent challenge or a delisting could pull it earlier, and new filings could push it later. Wegovy also holds 6 FDA exclusivities, 4 of which have expired, with the last outstanding one expiring in 2028 ^[3].

What did the Novo Nordisk v. Mylan lawsuit actually decide?

On July 22, 2025, Judge Connolly of the US District Court for the District of Delaware ruled in Novo Nordisk, Inc. v. Mylan Pharms. Inc., Civ. No. 23-101-CFC, on one piece of a much larger case ^[4][5]. Mylan had filed an ANDA seeking approval for a generic version of Wegovy, and Novo sued asserting five patents under the Hatch-Waxman Act, 35 U.S.C. § 271(e)(2)(A) ^[4][5].

The ruling itself was a Rule 12(c) judgment on the pleadings that Mylan does not infringe one of those five patents, US 9,764,003 ^[4][5]. The court also granted judgment of no direct infringement by Mylan as unopposed, and entered a stipulated judgment of no contributory infringement ^[5].

The ‘003 patent’s claim 1 covers a method for reducing body weight comprising administering semaglutide once weekly in an amount of at least 0.7 mg and up to 1.6 mg, “administered without another therapeutic agent” — that dose range is quoted patent-claim language, not dosing information ^[5]. The court construed the phrase to mean “without another therapeutic agent as part of the method for reducing body weight, or for treating the conditions of diabetes or hypertension” ^[5]. Because Mylan’s proposed label anticipated coadministration with drugs like insulin, insulin secretagogues, and antihypertensives, the label did not instruct the patented method ^[4][5][6].

The court also held that inducement requires an affirmative act of encouragement — the mere foreseeability that some physicians would prescribe the drug alone is not enough ^[5][6]. Legal analysts at Proskauer note that the “without another therapeutic agent” limitation was added during patent prosecution to overcome an obviousness rejection, and that in ANDA cases the proposed generic label is the primary evidence of intent to induce ^[6].

This ruling does not clear Mylan to sell generic semaglutide. It covered one patent out of five, at the pleadings stage, in a district court whose decision could be appealed ^[4][5]. Separately, Mylan and others had filed inter partes review petitions at the USPTO in March 2023 against the two semaglutide compound patents, US 8,129,343 and US 8,536,122, and institution was denied on October 2, 2023 ^[3].

Could semaglutide-like products arrive before the patents lapse?

Possibly, through the 505(b)(2) pathway rather than a true generic. A 505(b)(2) application is a full New Drug Application that relies on safety and efficacy data the applicant did not generate, referencing an already approved Reference Listed Drug ^[2]. DrugPatentWatch reports such programs typically cost $8 million to $20 million — 70% to 90% less than a full NDA — with approval timelines of 2 to 3 years, and the resulting product can be branded with 3 to 7 years of its own exclusivity ^[2].

Design-around targets include buffers and excipients, different maintenance doses, carve-out indications such as obstructive sleep apnea or MASH, and alternate delivery routes including oral formulations, microneedle patches, and implants ^[2]. Rybelsus’s oral absorption itself relies on the SNAC permeation enhancer (Eligen technology) ^[2]. Over 60 companies are developing GLP-1 drugs, including Pfizer, Amgen, and Viking Therapeutics ^[2].

These would be competing branded products, not interchangeable generics of Ozempic or Wegovy.

Does Rybelsus (oral semaglutide) run on a different clock?

The oral-related patents run later than the injection’s compound patent — though the dates come from Pharsight’s Wegovy listing, not a Rybelsus-specific patent list ^[3]. In that listing, the oral dosing method patents US 10,278,923 and US 12,239,739 run to May 2034, and the solid oral composition patents with the SNAC salt, US 11,833,248 and US 12,396,953, run to February 2039 ^[3]. Those SNAC-salt and oral-dosing patents are the ones tied to the tablet’s absorption technology, which relies on the SNAC permeation enhancer ^[2][3]. So even after the injectable compound patent expires in December 2031, the oral formulation and dosing patents extend several years beyond that ^[3].

When do Mounjaro and Zepbound go generic?

Tirzepatide is on a later clock than semaglutide. Its US composition-of-matter patent, US 9,474,780, expires January 5, 2036 ^[8]. I-MAK likewise puts the main tirzepatide compound patent at 2036, with follow-on patents extending protection to 2041, and counts 53 US patent applications filed by Eli Lilly with 16 patents granted on Mounjaro and Zepbound ^[1].

GreyB’s patent analysis shows a formulation patent, US 11,357,820, expiring June 14, 2039, with four active formulation patents restricting generic launch until 2039, and a delivery device patent, US 9,402,957, expiring June 29, 2031 ^[8]. Zepbound was approved by the FDA for chronic weight management on November 8, 2023 ^[8].

The telehealth company TrimRx projects that pediatric exclusivity could push tirzepatide’s composition protection to early 2037, notes that Lilly’s 10-K filings list US tirzepatide patents running from 2036 into the 2040s, and estimates the first US tirzepatide generic or biosimilar is unlikely before 2036 to 2038, with meaningful price drops more likely 2038 to 2040 ^[7]. Those are TrimRx’s projections, not official dates.

Why do peptide copies take longer than ordinary generics?

Semaglutide and tirzepatide are peptides, and copies of them face higher development hurdles than typical small-molecule generics. The two relevant US pathways are 505(b)(2) and the 351(k) biosimilar route ^[7]. Biosimilar development typically takes 7 to 10 years and costs $100 million to $250 million per program, according to TrimRx ^[7].

Peptide precedent, as laid out by TrimRx, is instructive. TrimRx notes that Forteo (teriparatide) saw its main US patent expire in 2018, but the first US generic, from Pfenex, did not launch until late 2020, and the price fell about 50% in the first 18 months ^[7]. TrimRx also cites Lantus (insulin glargine), which saw its first US biosimilar in 2016, with broader competition arriving over the following years ^[7]. Manufacturing is also a barrier: peptide synthesis is solvent-intensive and hard to scale, and DrugPatentWatch notes that a sponsor who patents a more efficient or “greener” manufacturing process gains a cost advantage that functions as a secondary moat after the primary patents expire ^[2].

What prices would a generic have to beat?

I-MAK reports Ozempic, Rybelsus, Wegovy, Mounjaro, and Zepbound are all priced at roughly $1,000 per month ^[1]. TrimRx cites Mounjaro and Zepbound brand list cash-pay prices at roughly $1,000 to $1,350 per month ^[7]. According to TrimRx, Lilly’s direct-to-consumer LillyDirect program offers self-pay Zepbound vials at $349 to $499 per month depending on dose, and TrimRx describes Novo Nordisk’s NovoCare program as the analogous Wegovy offering ^[7].

Those are the brand prices a US generic would have to undercut. There is no guaranteed percentage drop at generic entry — the roughly 50% Forteo decline over 18 months is one peptide example TrimRx cites, not a rule ^[7].

How big is the market a generic would enter?

DrugPatentWatch puts the global GLP-1 market at about $18.4 billion in 2024, projected to reach $156.7 billion by 2030 (a 17.46% compound annual growth rate), with an upper estimate of $261.2 billion by 2033 ^[2]. I-MAK expects the annual market to reach $130 billion by 2030 ^[1]. Patient volume is projected to grow from about 10 million in 2024 to 40 million by 2029, and Eli Lilly held approximately 57% of the market as of early 2025 ^[2]. Indications are also expanding beyond obesity into cardiovascular disease, chronic kidney disease, sleep apnea, and Alzheimer’s research ^[2].

What signals would actually move the US generic date?

A few concrete events matter more than any published estimate:

• Orange Book listings and delistings of device and formulation patents determine what a generic filer must challenge, and the FTC has already challenged device listings that do not recite the active ingredient ^[2].
• New ANDA filings with Paragraph IV certifications start the litigation clock, and listed patents can trigger a 30-month stay ^[2].
• Inter partes review at the USPTO is an alternate attack route — Mylan’s 2023 IPRs against the two semaglutide compound patents were denied institution in October 2023 ^[3].
• Appeals of the July 22, 2025 ruling, which decided one of five asserted patents at the pleadings stage, could reshape what remains in the case ^[4][5].
• Label carve-outs matter: as the Mylan ruling showed, method-of-use claims not supported by the generic’s proposed label are hard to enforce ^[6].

Any of these could pull the effective date toward December 2031 or push it toward the late 2030s and beyond. The compound patent expiry is the floor, not the forecast.

Sources

1. I-MAK. The Heavy Price of GLP-1 Drugs.
2. DrugPatentWatch. How to bypass the GLP-1 patent lock.
3. Pharsight by GreyB. Wegovy patent expiration.
4. Robins Kaplan LLP. Novo Nordisk, Inc. v. Mylan Pharms. Inc. July 22, 2025.
5. FindLaw. Novo Nordisk Inc v. Mylan Pharmaceuticals Inc. July 22, 2025.
6. Proskauer Rose LLP. Novo Nordisk v. Mylan: Method of Treatment Claims Must Be Aligned with Label. September 8, 2025.
7. TrimRx. When Will Tirzepatide Go Generic? Patent Timeline & Biosimilar Outlook. May 12, 2026.
8. GreyB. Mounjaro patent expiration: Drug patents expiring in 2036.
9. GenericHope. Semaglutide Price in India (2026): Generic Brands, Manufacturers & Cost Comparison.
10. IQVIA. The outlook for obesity from 2026 to 2030. April 21, 2026.
11. Dr Rajat Goel. Cost of Generic Semaglutide Injection in India 2026. March 30, 2026.
12. Manville News. News article on Canadian approval of first generic semaglutide.
13. Novo Nordisk. Financial report for the period 1 January 2026 to 30 June 2026. August 4, 2026.
14. The White House. Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States. April 2, 2026.
15. Reuters. Trump says generic drugs to face no US tariffs for 2 years, then 100% and 200% tariffs later. July 21, 2026.
16. BioPharma Dive. Trump threatens tariffs on imported generic drugs.
17. CNBC. As Americans go direct with GLP-1 prescriptions, Walmart, Costco, Amazon will be big weight-loss winners. August 1, 2026.
18. Medscape. Novo Nordisk to Halve US List Price Of Wegovy From 2027. February 24, 2026.
19. Centers for Medicare & Medicaid Services. Fact Sheet: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027. June 2023.